Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of SAR341402 vs NovoRapid and NovoLog in Type 1 Diabetes
NCT03202875Phase 1Completed
- Sponsor
- Sanofi
- Start
- Nov 2012
- Primary completion
- Dec 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin aspart in type 1 diabetes mellitus (T1D) (3 arms), sponsored by Sanofi. Primary endpoints: Maximum Plasma Concentration at 12 hours, Area Under the Concentration-Time Curve at 12 hours and 2 more. Started Nov 2012; status: completed.
02
Drugs
insulin aspart
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03202875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03202875.